ALTH 8k 10/25/07
sec.gov
On October 25, 2007, Allos Therapeutics, Inc.’s (the “Company”), issued a press release announcing the results from three PDX studies that were presented as posters during the 2007 AACR-NCI-EORTC conference held October 22-26, 2007 in San Francisco, California. The posters describe the effects of PDX (pralatrexate) in patients with non-small cell lung cancer (NSCLC), in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease, and in human cancer models in vivo and in vitro. The press release is attached hereto as Exhibit 99.1 and each of the posters, as presented, are attached hereto as Exhibits 99.2, 99.3 and 99.4, all of which are incorporated herein by reference and may also be used in meetings with investors and analysts after the date hereof and possibly with immaterial modifications. The fact that the posters are being furnished should not be deemed an admission as to the materiality of any information contained therein. The information contained in the posters should be considered in the context of our filings with the Securities and Exchange Commission and other public announcements that we may make, by press release or otherwise, from time to time.
The poster attached hereto as Exhibit 99.2 and entitled “Phase 1 study of the antifolate pralatrexate when given with vitamin B12 and folic acid supplementation in patients with advanced non-small cell lung cancer (NSCLC)” presented results of this Phase 1 dose ranging study. The poster attached hereto as Exhibit 99.3 and entitled “A Phase ‘2-1-2’ Study of Two Different Doses and Schedules of Pralatrexate, A High Affinity Substrate for the Reduced Folate Carrier (RFC-1), in Patients with Relapsed or Refractory Lymphoma Reveals Marked Activity in T-Cell Malignancies” presented additional interim data from the on-going study of PDX in patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and Hodgkin’s disease. The poster attached hereto as Exhibit 99.4 and entitled “Differential Activity and Potential Mechanism of Action of Pralatrexate (PDX), Methotrexate (MTX), and Pemetrexed (Alimta®) in Human Cancer Models In Vivo and In Vitro” presented results from a pre-clinical study that investigated the mechanism of action of PDX and its differences from other antifolates. The posters are available for viewing at the “Investor Relations” section of our website located at www.allos.com, although we reserve the right to discontinue that availability at any time.
Poster:
sec.gov
Poster:
sec.gov
Poster:
sec.gov |
